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Abstract: In the era of personalized medicine, the introduction of translational studies in clinical trials
has substantially increased their costs, but provides the possibility of improving the productivity
of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to
improve translational design for future gynecological cancer trials and of defining translational goals,
a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG)
Translational Research Committee and overall conclusions are here reported. A particular emphasis
was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion
pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial
design with standardization and optimization of procedures including a harmonization program of
Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and
ensured by dedicated funding. Biomarker validation and development should be made public and
transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for
patients’ informed consent are needed. Importantly for the public, recognized goals are to increase
the involvement of advocates and to improve the reporting of translational data in a forum accessible
to patients.
Keywords: translational studies design; gynecological cancers; biomarkers definition; precision
medicine; samples collection
1. Introduction
Current practice for gynecological cancers is based on the evidence generated by clinical trials
mainly designed without translational end-points. In the era of personalized cancer therapy, the
knowledge of patients’ tumor and germline molecular characteristics is becoming essential for a better
definition of a trial’s inclusion/exclusion criteria and better understanding and interpretation of the
results. Translational studies are often designed and performed after the corresponding clinical trial
has been completed, with translational end-points not included in the original study design with
the consequence that the collection of biological material is retrospective and not performed at study
entry or at diagnosis. Tissue samples collected at the end of patients’ recruitment might significantly
diminish the possibility of including all the intention-to-treat population in the translational analysis,
thus, compromising the possibility of having the right samples to answer the right question. Guidelines
and consensus on translational end-points and methodologies may improve the design of pivotal
trials minimizing the impact of bias. This manuscript provides a summary of the topics discussed
during the Gynecologic Cancer InterGroup (GCIG) Translational Research brainstorming day and
provides an overview of the consensus process together with ongoing questions/problems that remain
to be addressed.
2. Precision Medicine in Gynecological Cancer
What we expect from precision medicine is to contribute to our understanding of human cancer
biology and to define appropriated patient populations, based on their molecular characteristics, to
maximize the efficacy of personalized therapies. As a consequence, biospecimen-derived biomarkers
have increasingly been incorporated into therapeutic cancer clinical trials. However, the decision
to incorporate a biomarker into a clinical trial requires serious consideration of its advantages and
disadvantages as well as a careful choice of the most appropriate biomarker [1,2]. In addition to the
extremely important biological information that a biomarker may provide, some critical issues should
be taken into consideration during translational study design.
1. Translational studies can add complexity and may impact on recruitment to the clinical trial.
2. Clear definition of the hypotheses driving correlative studies is essential.
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3. The trial must be adequately designed and sufficiently powered to address the
translational hypotheses.
Clear guidelines are, therefore, needed to ensure the most accurate selection of reliable biomarkers
in terms of both detection and function in the clinic.
2.1. Biomarkers: Definitions and Applications
According to the Biomarkers Definitions Working Group [3], a biomarker is ‘a characteristic
that is objectively measured and evaluated as an indicator of normal biological processes, pathologic
processes, or pharmacologic responses to a therapeutic intervention’. Biomarkers can be specific cells,
molecules, genes, gene products, enzymes or hormones and need to fulfill three major criteria, to be:
practical, effective and reproducible.
Biomarkers have a number of applications, guiding disease prevention, diagnostic and prognostic
assessment, drug target identification, and drug response (Table 1). Among the different biomarkers,
the most frequently confused, in terms of applications and definitions, are prognostic versus predictive
markers. Prognostic markers inform about a likely outcome independently of any particular treatment.
Predictive markers are associated with benefit or lack of benefit from a specific therapy; they are of
particular relevance in personalized therapy as the treatment effect is different for patients with positive
or negative biomarker status. The interaction between the treatment effect and marker status can be
qualitative, when patients positive for the biomarker benefit from the treatment but the others receive
no benefit or possibly even harm, or quantitative, when treatment benefits all patients but by different
amounts. Qualitative interaction can clearly help in guiding treatment choice, whereas in the case of
quantitative interaction it is more difficult to establish whether or not the biomarker will be useful for
selection of a new treatment because both patient subgroups derive some benefit from treatment.
Table 1. Biomarker applications.
Type of Biomarker Question Addressed
Diagnostic Cancer type/subtype identification
Prognostic Cancer outcome definition
Predictive Probability of response to a given drug
Pharmacodynamic Definition of the optimal dose for efficient target engagement
Biomarkers can also be divided into integral, integrated, and exploratory, each having their
specific requirements (Table 2). Integral biomarkers must be identified a priori for the trial to proceed
(e.g., a particular biomarker status may be a pre-requisite for patient entry or required for stratification).
Such biomarkers are inherent to the trial design and must be performed in real time, to underpin the
conduct of the trial. Integrated biomarkers are those clearly specified to address pre-stated hypotheses.
Often they are intended to identify or validate assays or markers that are planned for use in future
trials. Their design should be as precise as for integral biomarkers, but the assay result is not used for
eligibility or treatment assignment in the current trial. Exploratory biomarkers are only descriptive in
the perspective of alternative treatments.
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Table 2. Biomarkers definition.
Aims Requirements
Integral Used for patient selection within a particular trial;its detection determines patient treatment.
Assessment has to be performed in a CLIA
environment; it may require IDE and
additional FDA approval.
Integrated
Used for patient/tumor characterization;
it should provide evidence of
function/pathway alteration.
CLIA environment recommended;
IDE is not required.
Exploratory
Descriptive biomarkers; used to explore other
patient characteristics useful for
alternative treatment(s).
No particular requirements to be performed.
Abbreviations; CLIA: Clinical Laboratory Improvement Amendments; IDE: Investigational Device Exemption.
A biomarker, to be considered integral, needs to be validated from preclinical observation to
clinical application (Figure 1). Proceeding through phase II-III trials, the first priority is to establish the
efficacy of the novel agent. The identified biomarker must then have sufficient predictive power to
allow patient selection. The ideal validation of a predictive biomarker is the demonstration that an
agent is more effective than standard therapy in biomarker-positive patients and no more effective than
standard therapy in biomarker-negative patients. This 2 × 2 approach (randomization) relies upon a
positive test for interaction and prevents prognostic biomarkers from being mistaken for predictive
biomarkers. In the corresponding trial design, only biomarker-positive patients will be randomized to
treatment. In this situation, it is important to be confident regarding correct biomarker selection and
to be aware of the potential for responsive patients to exist in the biomarker-negative group due to
treatment effects not directly related to biomarker expression and/or activity.
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Figure 1. Paradigm for use and definition of biomarkers in clinical trials. Validation of a biomarker to be
considered integral to a clinical trial from its pre-clinical definition. Slide courtesy of Dr. A. Oza from his
presentation to the Gynecologic Cancer InterGroup (GCIG) Translational Research brainstorming day.
An excelle t example of biomarkers application is the ENGOT OV-16 NOVA trial [4] of
maintenance therapy for High-grade Serous Ovarian Cancer (HGSOC); it included integral, integrated,
and exploratory biomarkers.
The integral biomarker was the detection of germline BRCA1/2 mutation before randomization
for treatment with a PARP inhibitor vs. placebo. In the BRCA1/2 germline wild type arm, an integrated
study was nested, which characterized tumors according to homologous recombination deficiency
(HRD) status and allowed assessment of treatment efficacy in the HRD-positive population in terms
of progression-free survival (PFS). Finally, an exploratory analysis of PFS was performed in specific
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subgroups of the BRCA1/2 germline wild type cohort, defined by taking into account the HRD status
(positive vs. negative) and the presence of somatic BRCA1/2 mutation vs. BRCA1/2 wild type in the
HRD-positive cohort (Figure 2).
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Figure 2. Application of integral, integrated and explorative biomarker analysis in the
ENGOT-OV-NOVA16 trial design. (gBRCA: germline BRCA; mut: mutated; HRD: homologous
recombination deficiency).
2.2. Biospecimen, Quality Control, and Validation
Identification of appropriate targets for tumor detection, therapy and prevention rely on our
ability to generate high-quality patient-derived specimens whose collection, storage, handling, and
processing must be well controlled to prevent assigning clinical significance to artefactual findings.
There sho ld e a commitment to o timize quality in biomarker detection t maximize the chance
of successful validation. This involves ensuring that the procedures for the entire biomarker pipeline
are accurate, standardized, and reproducible (including sample collection, processing, assay, scoring
system, and threshold selection). Analytical validation of an assay involves assessment of accuracy,
precision, specificity, and sensitivity to ensure sufficient intra- and inter-laboratory reproducibility.
Furthermore, moving from preclinical models to human patients, the assay should fit for use on clinical
specimens. An approved reference standard that can be use for the developme t/validation of the
assay is recommended.
The choice of the appropriate clinical trial strategy depends on the strength of the existing
evidence for the biomarker (the biomarker credentials) and the questions being addressed (clinical
endpoints). Basic designs of randomized phase III biomarker-driven trials with time-to-event end
point (overall survival, disease-free survival, relapse free survival) include biomarker-enrichment and
biomarker-stratified designs, with adaptive designs being increasingly incorporated (Table 3).
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Table 3. Biomarkers credentials.
Biomarker-Enrichment Design Biomarker-Stratified Designs Adaptive Designs (Randomized Phase II/III Trial Design)
Design description
• Biomarker positive subgroup is tested.
• Control/standard therapy arm controls for marker
prognostic effects.
• Randomize for treatment both positive and
negative patients.
• Several different testing strategies
are possible.
• Combine phase II and phase III trials in a phase II/III trial.
• It can be used without enrichment or be stratified
by biomarker
Suitable choice when
• Solid knowledge of biomarker biology.
• Convincing evidence that the benefits of treatment
are limited to the biomarker-positive subgroup.
• A clinically significant effect in
biomarker-negative patients cannot be ruled out.
• The treatment benefit should be definitively assessed;
• It allows a decrease of the time and number of patients
required from early to later phase development.
Major issues:
• It does not provide information on the
biomarker-negative population (off-target effects,
multiple pathway targeting)
• Advantages coming from biomarker refinement
within trial are limited to biomarker-positive patients.
• They maintain a good statistical power even
in the case of a homogeneous treatment effect
across subgroups.
• They provide evidence of treatment benefit
in both positive and negative population.
Interim analysis can guide the accrual of
biomarker-negative subgroup.
Critical are
• the choice of the intermediate endpoint
• the criteria (error rates, timing of analyses) defining a
promising activity for phase II
• accrual suspension while awaiting phase II data to mature.
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Advances in the omics era posed a considerable challenge for the definition of clinical trial
strategies. Indeed, the evaluation of a targeted treatment in the early development phase required
accurate selection of the patient population and led to smaller trials, resulting in smaller datasets on
which to build the body of evidence necessary to support the use of a drug/therapeutic agent for a
particular indication. To address this, new clinical trial designs were developed:
Basket studies: Patients are selected according to their molecular characteristics and biomarkers,
regardless of the site of origin of their tumor. Usually, they focus on a single drug targeting a single
biomarker in different tumors. An example is BRAF V600 Vemurafenib enrolling patients with different
non-melanoma cancers harboring BRAF V600 mutation [5].
Umbrella studies: They enroll patients with a single tumor type, defined by primary anatomic site,
and direct them towards different treatments according to the molecular characterization of each case.
An example is the FOCUS4 study in colorectal cancer, which stratifies patients according to biomarker
positivity or negativity into seven different randomizations, the last of which is for patients not yet
stratified by any of the preceding biomarkers [6].
Platform trials: As in the case of umbrella trial, the focus is on the disease rather than on a particular
type of therapy but, rather than assuming that we know which drug is appropriate for which biomarker
stratum, randomization among drugs is used in the platform trial. They can be considered as an
extension of adaptive trials as accumulating outcome data can be used to adjust randomization to
assign the better performing treatment regimen. An example is the BioRAIDs trial on cervical cancer
whose challenge was to identify potentially curative therapeutic interventions based on a rational
molecular assessment leading to the design and selection of innovative drugs [7].
2.3. Improvement of Biomarker Development
Longitudinal collection of tissue and liquid biopsy, imaging, and robust clinical data annotation
are key elements for the achievement of an integrated, personalized medicine strategy. The BriTROC-1
prospective observational study [8] involving 12 cancer centers across the UK addressed this challenge
by profiling multiple samples (blood and tissue) from 300 patients with high grade serous ovarian
cancer (HGSOC) during the course of their disease (at diagnosis, at the end of therapy, and upon
relapse) to:
• Assess longitudinally, cancer cell clonal evolution and dynamics in cohorts or individual cancer
patients and to capture heterogeneity in space and time [9].
• Guide the use of molecular-targeted therapies and provide critical insight into mechanisms of
treatment failure and resistance in cancer patients.
It has to be taken into consideration that longitudinal clinical studies are complex and require
dedicated personnel, expert in activities over the ‘routine’ clinical trial (e.g., coordinating multiple
parallel clinic/diagnostic/biopsy appointments, entering eCase Report Forms). Liquid biopsies appear
to be an attractive approach for longitudinal analyses. However, techniques, such as cell free DNA
(cfDNA) analysis, that can be performed on liquid biopsy still require refinement and validation.
In high-grade serous ovarian cancer, TP53 mutation is an obvious candidate for such validation, as it
is almost ubiquitously mutated and can be detected immunohistochemically and by sequencing in
tumors as well as in cfDNA [10].
A further valuable example derives from the TransPORTEC consortium: An international
collaborative group with multidisciplinary experts (clinical, radiation, medical and gynecological
oncologists, pathologists, scientists, and statisticians) working on endometrial cancer with the aims
to discover: (1) molecular prognostic factors, (2) predictors of chemotherapy efficacy, (3) immune
response markers (4) new targets for therapy, and (5) driver mutations, and mechanisms of endometrial
cancer development and spread. The PORTEC-1 and PORTEC-2 trials together recruited about 1000
stage I-II endometrial cancer patients with high–intermediate risk factors to evaluate the role of pelvic
radiotherapy (PORTEC-1) vs. vaginal brachytherapy (PORTEC-2). Translational studies derived from
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PORTEC-1/2 trial biobank, incorporating comprehensive analysis of molecular factors, have led to
improved risk assessment of endometrial cancer [11].
A centralized prospective biobank with well-defined methods and processes was put in place
with patient consent covering the donation of tissues sample. Together with archival fixed histologic
tumor material, matched tumor, and normal DNA was collected for each patient. Expert pathology
review was performed to ensure adequate assessment of pathological factors, thus, facilitating the
establishment of a molecular integrated risk assessment model. In the integrated model, besides the
existing “big five” pathologic assessments (tumor type, grade, myometrial involvement, endocervical
involvement, and lympho–vascular space invasion), immunohistochemistry for key molecules as well
as molecular features, have been included [11]. These analyses allowed the identification of three
molecular integrated risk profiles: (1) unfavorable, (2) intermediate, (3) favorable, reclassifying about
70% of endometrial cancer patients. In the PORTEC-3 trial, upfront expert pathology review was
mandatory before the inclusion of a patient in the trial to ensure a true high-risk population [12].
The TransPORTEC biobank now contains over 400 tissue samples donated by women participating in
the trial. To prepare for translational research with the PORTEC-3 trial samples, the consortium worked
to put the logistics, including an application for funding, into place for international collaborative
biomarker studies and to generate hypotheses for further research. As a result, a new trial, PORTEC-4,
has been initiated to compare individual molecular integrated therapy with standard indications for
the most appropriated adjuvant treatment.
3. Immunoprofiling of Gynecological Cancers: Towards a New Class of Biomarkers?
Cancer is characterized by the accumulation of genetic alterations resulting in the expression
of neoantigens that could be presented on the surface of cancer cells in association with a major
histocompatibility complex (MHC), thus, distinguishing them from their normal counterparts and
stimulating an immune response [13,14]. Identification of the mechanisms by which tumor cells
adapt to evade the anti-tumor immune response may help in rational drug development and
treatment selection for personalized cancer immunotherapy [15]. Some tumors might not be
infiltrated by immune cells (so-called ‘cold tumors’) and in the cases where immune cell infiltration is
present; three major players could contribute to their activity: the type of immune infiltrate, tumor
microenvironment-specific factors, and antigen presentation machinery. Understanding and defining
the immune profile of a patient’s tumor is key to exploiting it.
3.1. Tumor-Infiltrating Immune Cells
The association of tumor-infiltrating lymphocytes (TIL) with improved ovarian cancer prognosis
was initially described by G. Coukos and colleagues [16] and confirmed by a meta-analysis of ten
studies including 1815 OC patients [17]. However, to be effective, immunotherapy-based strategies
need to accurately characterize the different TIL populations to identify which population should
be targeted or stimulated. Indeed, mainly cytotoxic TIL were those associated with prolonged
survival [18], while the presence of high numbers of intratumoral immunosuppressive regulatory T
cells, inhibiting the T cell-mediated anti-tumor response, was associated with worse outcome [19].
The evidence that the local (immune microenvironment) and systemic host T cell immune profile could
be significantly different [20] highlighted the relevance of considering both profiles when designing
immunotherapeutic strategies.
3.2. Tumor-Specific Factors
Mechanisms that limit immune responses toward a cancer, essentially act by inhibiting cytotoxic
T cell effects and there are a number of immune-checkpoints which regulate interactions between T
cells, antigen presenting cells, cells of the innate immune system, such as macrophages, and tumor
cells. Among the immune-checkpoints, PD-L1 expression on tumor cells represents a major immune
evasion strategy for many cancers. Indeed, binding of the check-point molecule, PD-1, expressed
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by T cells, to its ligand PD-L1, expressed by tumor cells, prevents T cell receptor activation [21].
Therefore, antibodies directed against PD-1 expressed on T cells and/or antibodies directed against
PD-L1 expressed on tumor cells, preventing the ligand-receptor binding could ‘release the brake’ and
permit T cell activation.
In ovarian cancer patients, the prognostic role of PD-L1 expression on tumor cells appears to
be contradictory [22,23]. In this complex setting, identifying ovarian cancer patients with a high
number of the specific T cell subpopulation that could mostly respond to stimulation by acting on
checkpoint molecules, could be a strategy to identify those patients who could most benefit from
this type of treatment [24]. It would also be very helpful to understand which histopathological or
molecular (clear cell carcinoma or BRCA1-mutant HGSOC) subsets of ovarian and other gynecological
cancers (mismatch repair (MMR) deficient endometrial cancer) are primed to respond to immune
checkpoint inhibitors.
3.3. Tumor Antigenicity
Neo-antigens are non-self-antigens, typically derived from tumor-specific somatic mutations and
can be targeted by the host immune system. Advances in sequencing technology, which allow the
direct identification of tumor neoantigens, can now be exploited for immune therapy. Hyper-mutated
cancers such as melanoma, lung cancer or tumors with MMR deficiency, harboring a high number of
tumor-specific neo-antigens, stimulate the recruitment of TIL and have high response rates to treatment
with immune checkpoint inhibitors. Ovarían cancer typically harbors a low to intermediate mutational
burden, with few bona fide MHC-presented epitopes [14]. Indeed, bioinformatic analysis of TCGA data
revealed that only 12% of HGSOC cases had a 90% likelihood of harboring at least one authentically
processed and presented neoantigen, versus 51% of lung cancers [25]. The analysis further showed that
HRD tumors (including those with BRCA1/2 mutations) exhibit higher neo-antigen load compared to
HR proficient tumors [26].
In this context, an interesting example arises from a phase II study on the effect of pembrolizumab
(anti-PD1) treatment in tumors with MMR deficiency, in patients with treatment-refractory progressive
metastatic cancers [27,28]. A higher objective response rate was observed in patients with MMR
deficiency whose somatic mutational load (detected by whole exome sequencing) was 200 fold higher
than in MMR proficient patients. This hypermutated phenotype resulted in the expression of a high
number of neoantigens increasing immunogenicity, thus, boosting an immune response and favoring
efficacy of pembrolizumab. Interestingly, among the non-colorectal cancers included in the phase
II study, were two endometrial cancer cases. Endometrial cancers have been recently classified in
four molecular distinct subtypes with prognostic relevance [29] including a molecular subgroup with
MMR deficiency and a subgroup with an excellent prognosis characterized by mutation of the DNA
polymerase POLE involved in proofreading of DNA during DNA replication. POLE mutation causes
an ‘ultra-mutated’ phenotype increasing immunogenicity and promoting a more favorable outcome,
with likely sensitivity also to checkpoint inhibition-based treatment [30].
3.4. Reactivating the Immune System
Reactivation of inert T cells would be expected to substantially improve management of
gynecological malignancies, and it is, indeed an area of active investigation. T cells activity could
be regenerated by reactivating the immune system by vaccination. Neoantigens with the ability to
activate an immune response can be directly identified by sequencing technology and bioinformatics
pipelines [25] and exploited for vaccination therapy [31]. Within gynecological malignancies, a number
of therapeutic vaccines based on the targeting of HPV E6 and E7 early proteins are under investigation
supported by preclinical results [32].
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3.5. Microenvironment and Immune Responses
The presence of an immunosuppressive environment, due to tumor-infiltrating myeloid cells, such
as tumor-associated macrophages, has increasingly been recognized as impacting on ovarian cancer
response to treatment. Tumor-derived factors actively recruit circulating monocytes at the tumor site
where they differentiate into tumor-associated M2 macrophages promoting tumor cell proliferation and
survival. Targeting immuno-suppressive M2 macrophages or activating tumoricidal M1 macrophages
are attractive immunotherapeutic strategies with the potential for generating valuable anti-tumor
responses [33,34].
4. Overcoming Roadblocks to Completing Translational Goals
Parallel breakout working groups, enriched with relevant expertise, focused on topics related to
tumor tissue collection and analysis, requirements for appropriate validation of predictive biomarkers,
legal and ethical issues. The aim was to develop recommendations on how to overcome potential
roadblocks to facilitate the achievement of translational goals in gynecological research. The main
points discussed are itemized below.
1. Pathology and biomarker research should be integral to clinical trial design to reduce the
likelihood that a trial produces a negative result without mechanistic information provided.
2. Mandatory upfront central collection of pathologically reviewed patients’ tissues is to be preferred
to ensure the generation of optimal trial-associated tumor biobanks with complete clinical
annotation. Efforts should be made to create a harmonization program of Standard Operating
Procedures (SOPs) to be shared across trial centers and across GCIG members as a set of
documented guidelines taking into account issues related to sample collection, curation, and
clinical data annotation.
3. When planning a collaborative translational study, two different scenarios could be hypothesized,
a virtual vs. physical biobanking, each of them requiring different costs, management, and
governance. In the process of selection of the most appropriate type, it should be considered
that while the virtual biobanking is easy from a regulatory perspective with tissues remaining
in the original sites, it needs the development of robust protocols for testing the biomarkers, as
the assays will be all carried out locally. In addition, while it is useful for validation studies, the
virtual biobanking is not practical for rarer tumor types or small trials.
4. Expert pathology review is recommended to ensure comprehensive assessment of gynecological
cancers [35]. When considering a trial design which includes molecular tests it is recommended
that translational/molecular/pathologic expertise should be consulted, to optimize sample
collection and translational study design. In any case, the development of a project-specific
consortium with a defined data-sharing mechanism, authorship policy and regular meetings,
may substantially improve the output of the translational study.
5. A process of assay validation is required with regard to reproducibility and reliability between
laboratories (use of different/multiple platforms across different labs), to validate fit-for-purpose
assay platforms, analysis tools, shared controls, and cut points that should be used in the final
setting assay.
6. As new analyses are developing over time, studies with molecular end-points should include as
part of the trial, pathology-reviewed collection of additional biospecimen(s) for future use, for
assay revalidation, and assessment of new or improved biomarkers.
7. Biomarker validation and development are related processes that should be made public and
transparent at all points by all stakeholders (including industry) to ensure rapid progress with
positive outcomes for patients. The early phase studies should include all-comer, non-randomized
patients, assessing intra and inter patient heterogeneity (temporal and geographic heterogeneity).
In early validation studies, evaluation of the full spectrum is preferable to avoid loss of
information about the possible treatment effect in the biomarker-negative population, these
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studies can be single arm and relatively small. Progression toward validation should be based
on randomization, focused on the population of interest, with adequate power for appropriate
treatment/outcome interaction analyses.
8. Patient consent has to be specific and explicit, referring to future relevant research. However, to
improve its acceptance, it should be a one-time consent, remaining broad but yet not unlimited in
its terms. The opportunity to introduce a tiered consent has been considered. Potential exemption
of consent should be considered (Declaration of Helsinki, art 32) with the development of an
ethically defensible plan.
9. Engagement of multiple trial groups with the aim of streamlined tissue donation and curation
should be advocated, to increase the value/impact of trials through translational research. This is
particularly aimed at ending the waste of funding and effort associated with trials which fail to
reach their primary or secondary endpoints
Along with these suggestions, important methodological issues still need to be solved.
• Standardization of the process of selection and optimization of the cutoff point for
continuous biomarkers.
• In addition to scientific validity, the cost-benefit impact of biomarkers should also be considered.
Whenever possible, based on anatomic feasibility, collection of post-progression biopsies should
always be included in patient consent forms. Since this procedure is often restricted due to lack of
funding, parallel institutional or trial group protocols and funding should be made available to
ensure this collection.
• Issues related to the heterogeneity of the tumor and of the host (ethnic/racial variation) need to
be considered.
• The use of an agreed governance document for Material Transfer is important to simplify
institutional intellectual property agreements and to reduce delay.
• The creation of a big data consortium for clinical trial data to overcome the limitations related to
the poor diffusion of negative results and to the different regulatory issues existing among the
different entities involved should be considered.
5. Conclusions, Overall Goals and Key Future Tasks
The GCIG–Translational Research brainstorming day provided the opportunity for international
discussion and consensus on important issues related to the inclusion of translational end-points
into clinical trial designs for gynecological malignancies. Standardization and optimization of
procedures for such molecular analyses are, therefore, needed, and summarized below, to maximize
patients’ benefit.
• Development of a harmonization program of SOPs in a set of documented trial-specific guidelines
taking into account issues related to sample collection and curation (pathological definitions and
evaluation, clinical data annotation), and biomarker validation (analysis tools, choice of cut-points,
impact of geographical and temporal heterogeneity, platforms, laboratory variation, etc.)
• Improve data sharing, transparency (e.g., components of biomarker signature/algorithms)
publications (including negative findings) and ensure funding for sample collection. Facilitate
development of consortia with a constitution, a data sharing mechanism and authorship policy
that might also improve translational research funding success.
• GCIG guidelines/templates for patients’ informed consent including incorporation of global
GCIG Material Transfer Agreement for widespread use to ensure streamlined access to patient
specimens for the purpose of translational research.
• Increase involvement of advocates and improve reporting of translational data in a forum
accessible to patients.
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